Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy

Journal of Urology

Volumn 186, Issue 5, 2011, Pages 2094-2100

  Wosnitzer, Matthew S ^a   Domingo Domenech, Josep ^b   Castillo Martin, Mireia ^b   Ritch, Chad ^a   Mansukhani, Mahesh ^b   Petrylack, Daniel P ^b   Benson, Mitchell C ^a,b   McKiernan, James M ^a,b   Cordon Cardo, Carlos ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

BCG vaccine; carcinoma; stathmin; tau proteins; transitional cell; urinary bladder

Indexed keywords

BCG VACCINE; DOCETAXEL; INTERFERON; KI 67 ANTIGEN; NANOPARTICLE; PACLITAXEL; PROTEIN P53; STATHMIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ARTICLE; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MICROTUBULE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; BRIDGED COMPOUNDS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MICROTUBULES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; STATHMIN; TAU PROTEINS; TAXOIDS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 80053958687     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.06.051     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. J.N. Eble Pathology and genetics of tumours of the urinary system and male genital organs World Health Organization Classification of Tumours 6th ed. 2004 IARC Press Lyon 359
3. R.J. Sylvester, A.P. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466
4. A. Bohle, and P.R. Bock Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682
5. M.S. Cookson, H.W. Herr, and Z.F. Zhang The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62
6. M.A. O'Donnell, J. Krohn, and W.C. DeWolf Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed J Urol 166 2001 1300
7. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398
8. R. Addeo, M. Caraglia, and S. Bellini Randomized phase III trial on gemcitabine versus mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance J Clin Oncol 28 2010 543
9. G. Steinberg, R. Bahnson, and S. Brosman Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder The Valrubicin Study Group J Urol 163 2000 761
10. J.M. McKiernan, P. Masson, and A.M. Murphy Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy J Clin Oncol 24 2006 3075
11. L.J. Barlow Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer J Clin Oncol 28 2010 4542
12. R. Golouh, T. Cufer, and A. Sadikov The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study Breast Cancer Res Treat 110 2008 317
13. K. Mimori, N. Sadanaga, and Y. Yoshikawa Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment Br J Cancer 94 2006 1894
14. R. Rouzier, R. Rajan, and P. Wagner Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer Proc Natl Acad Sci USA 102 2005 8315
15. D. Su, S.M. Smith, and M. Preti Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel Cancer 115 2009 2453
16. A. Lopez-Beltran, R.J. Luque, and J. Alvarez-Kindelan Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1) Eur Urol 45 2004 606
17. M.D. Weingarten, A.H. Lockwood, and S.Y. Hwo A protein factor essential for microtubule assembly Proc Natl Acad Sci USA 72 1975 1858
18. J.L. Ross, C.D. Santangelo, and V. Makrides Tau induces cooperative Taxol binding to microtubules Proc Natl Acad Sci USA 101 2004 12910
19. P.K. Davis, and G.V. Johnson The microtubule binding of Tau and high molecular weight Tau in apoptotic PC12 cells is impaired because of altered phosphorylation J Biol Chem 274 1999 35686
20. P.A. Loomis, T.H. Howard, and R.P. Castleberry Identification of nuclear tau isoforms in human neuroblastoma cells Proc Natl Acad Sci USA 87 1990 8422
21. C.I. Rubin, and G.F. Atweh The role of stathmin in the regulation of the cell cycle J Cell Biochem 93 2004 242
22. R. Ghosh, G. Gu, and E. Tillman Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression Prostate 67 2007 1038
23. Y. Kouzu, K. Uzawa, and H. Koike Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis Br J Cancer 94 2006 717
24. R.H. Yuan, Y.M. Jeng, and H.L. Chen Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma J Pathol 209 2006 549
25. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323
26. A. Vazquez, L.F. Grochola, and E.E. Bond Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival Cancer Res 70 2010 172
27. H.K. Seo, K.S. Cho, and J. Chung Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy Urology 76 2010 512.e1
28. N.N. Lynn, M.C. Howe, and R.J. Hale Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy J Urol 169 2003 721
29. P. Gazzaniga, A. Gradilone, and E. de Berardinis A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer BJU Int 104 2009 184
30. D.A. Hausladen, M.A. Wheeler, and D.C. Altieri Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome J Urol 170 2003 230